Pasithea Therapeutics Corp’s recent filing unveils that its Director STEINMAN LAWRENCE acquired Company’s shares for reported $100000.0 on Nov 28 ’25. In the deal valued at $0.75 per share,133,333 shares were bought. As a result of this transaction, STEINMAN LAWRENCE now holds 199,691 shares worth roughly $0.23 million.
Then, Marques Tiago bought 33,333 shares, generating $25,000 in total proceeds. Upon buying the shares at $0.75, the Chief Executive Officer now owns 73,334 shares.
Before that, Dumesnil Simon bought 33,333 shares. Pasithea Therapeutics Corp shares valued at $25,000 were divested by the Director at a price of $0.75 per share. As a result of the transaction, Dumesnil Simon now holds 35,833 shares, worth roughly $41566.28.
Price Performance Review of KTTA
On Monday, Pasithea Therapeutics Corp [NASDAQ:KTTA] saw its stock fall -21.09% to $1.16. Over the last five days, the stock has gained 296.85%. Pasithea Therapeutics Corp shares have fallen nearly -61.46% since the year began. Nevertheless, the stocks have fallen -63.17% over the past one year. While a 52-week high of $3.85 was reached on 02/05/25, a 52-week low of $0.28 was recorded on 11/21/25.
Levels Of Support And Resistance For KTTA Stock
The 24-hour chart illustrates a support level at 1.0567, which if violated will result in even more drops to 0.9533. On the upside, there is a resistance level at 1.3667. A further resistance level may holdings at 1.5733.
How much short interest is there in Pasithea Therapeutics Corp?
A steep rise in short interest was recorded in Pasithea Therapeutics Corp stocks on 2025-11-14, growing by 427.0 shares to a total of 23343.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 22916.0 shares. There was a rise of 1.83%, which implies that there is a positive sentiment for the stock.
